诺诚健华:全资子公司与礼来签署授权许可协议,协议包含至多32.5亿美元的里程碑付款

格隆汇
Sep 24
诺诚健华公告,公司的全资子公司北京诺诚健华医药科技有限公司与Eli Lilly and Company签署研发合作及授权许可协议,双方将在创新药物研发领域开展战略合作,公司将依托专有药物发现平台及深厚的研究经验,发现并开发至多5项创新性靶点项目,以解决重大未满足的临床需求。礼来公司将向公司支付最高1亿美元的首付款和近期里程碑付款。潜在的研发及商业化里程碑付款总额合计约32.5亿美元。此外,公司有权按许可产品年度净销售额收取个位数百分比的分级特许权使用费。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10